Vertex Pharma (Nasdaq: VRTX) announced that the European Commission has approved KALYDECO (ivacaftor) for people with cystic fibrosis (CF) ages ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE